Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)
Key facts
- Where
- Calgary, Markham, Ottawa, and Toronto, CanadaSee the 4 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT06568367, who can take part
Where in Canada
- Calgary, AlbertaHospital not named in the registryContact: Study DirectorTaking people
- Markham, OntarioHospital not named in the registryContact: Study DirectorTaking people
- Ottawa, OntarioHospital not named in the registryContact: Study DirectorTaking people
- Toronto, OntarioHospital not named in the registryContact: Study DirectorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Axsome Therapeutics, Inc.
- Trial code
- NCT06568367
- Record updated
- 24 July 2026
- Original description
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).Read full original descriptionShow less
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder
SUSTAIN (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder) is a Phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel- group trial to assess the efficacy and safety of solriamfetol in adults with excessive sleepiness associated with shift work disorder (SWD).
Inclusion: Meets International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria for Shift Work Disorder (SWD); Provides written informed consent to participate in the study before the conduct of any study procedures; Male or female, aged 18 to 65 inclusive.
Exclusion: Prior exposure to solriamfetol/Sunosi, through either a clinical study or prescription; Unable to comply with study procedures; Medically inappropriate for study participation in the opinion of the investigator.